| MARS2 |
|---|
| Gene Symbol | MARS2 |
| Full Name | Mitochondrial Arginyl-tRNA Synthetase 2 |
| Chromosomal Location | 2q33.1 |
| NCBI Gene ID | [92935](https://www.ncbi.nlm.nih.gov/gene/92935) |
| OMIM | [609446](https://www.omim.org/entry/609446) |
| Ensembl ID | ENSG00000135953 |
| UniProt ID | [Q9N3W4](https://www.uniprot.org/uniprot/Q9N3W4) |
| Associated Diseases | Spastic Paraplegia (SPG74), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Parkinson's Disease](/diseases/parkinsons-disease), Mitochondrial Disorders |
MARS2 (Mitochondrial Arginyl-tRNA Synthetase 2) encodes a mitochondrial aminoacyl-tRNA synthetase (mtARS) that specifically charges arginine to its cognate mitochondrial tRNA. Mitochondrial aminoacyl-tRNA synthetases are essential enzymes that catalyze the attachment of amino acids to their respective tRNA molecules, a critical step in mitochondrial protein synthesis. These enzymes are distinct from their cytosolic counterparts and are encoded by nuclear genes but function within the mitochondrial matrix. MARS2 is one of several mtARS genes linked to neurodegenerative diseases, including hereditary spastic paraplegia (HSP) and amyotrophic lateral sclerosis (ALS). Mutations in MARS2 cause autosomal recessive hereditary spastic paraplegia type 74 (SPG74), characterized by progressive lower limb spasticity and mitochondrial dysfunction. The enzyme's role in maintaining mitochondrial translation makes it critical for neuronal survival, particularly in long projection neurons that are affected in HSP and ALS.
MARS2 encodes mitochondrial arginyl-tRNA synthetase 2, a nuclear-encoded enzyme that functions in the mitochondrial matrix to charge arginine to mitochondrial tRNA. This enzymatic function is essential for the translation of the 13 oxidative phosphorylation (OXPHOS) proteins encoded by mitochondrial DNA. MARS2 mutations cause autosomal recessive hereditary spastic paraplegia type 74 (SPG74), presenting with progressive spasticity and gait disturbance. The disease mechanism involves impaired mitochondrial translation leading to OXPHOS deficiency, reduced ATP production, and increased susceptibility to oxidative stress. Given the high energy demands of neurons, particularly long axonal projection neurons, mitochondrial translation defects have profound consequences for neuronal viability. MARS2 represents one of several mtARS genes implicated in neurodegeneration, highlighting the importance of mitochondrial protein synthesis for neuronal health.
MARS2 catalyzes the aminoacylation reaction:
L-arginine + tRNA(Arg) + ATP → Arg-tRNA(Arg) + AMP + PPi
This reaction occurs in the mitochondrial matrix and is essential for mitochondrial translation.
Human MARS2 protein properties:
- Length: Approximately 577 amino acids
- Molecular weight: ~65 kDa
- Domains: Contains the catalytic domain typical of class I aminoacyl-tRNA synthetases
- Mitochondrial targeting: N-terminal mitochondrial targeting peptide (MTS)
MARS2 functions in mitochondrial translation:
- tRNA aminoacylation: Specifically charges mitochondrial tRNA(Arg) with arginine
- Codon-anticodon matching: Recognizes AGA and AGG arginine codons in mitochondrial DNA
- Ribosome function: Provides correctly charged tRNAs for translation of mtDNA-encoded proteins
MARS2 mutations cause autosomal recessive HSP:
-
Clinical features: Progressive spasticity of lower limbs, gait disturbance, intellectual disability in some cases
-
Genetics: Biallelic loss-of-function mutations (nonsense, frameshift, splice-site)
-
Pathogenesis: Impaired mitochondrial translation leads to OXPHOS deficiency
-
Neuronal vulnerability: Long corticospinal tract neurons are particularly affected
MARS2 is implicated in ALS:
- Mitochondrial dysfunction: Common feature in ALS motor neurons
- OXPHOS defects: Reduced complex I and IV activity in patient tissues
- Energy deficit: Reduced ATP production compromises motor neuron survival
- Oxidative stress: Impaired mitochondria produce increased ROS
Mitochondrial translation defects in PD:
- Dopaminergic neuron vulnerability: High energy demands make them susceptible
- Complex I deficiency: Related to impaired mitochondrial translation
- PINK1/Parkin connection: Links to mitochondrial quality control
MARS2 is expressed in tissues with high mitochondrial energy demands:
- Brain: Cortex, hippocampus, basal ganglia, spinal cord
- Heart: High expression in cardiac muscle
- Skeletal muscle: High expression in muscle fibers
- Liver: Substantial expression in hepatocytes
- Kidney: Renal tubular cells
In the nervous system:
- Neurons: High expression in pyramidal neurons and motor neurons
- Astrocytes: Moderate expression
- Oligodendrocytes: Important for myelin production
- Microglia: Lower expression
| Partner |
Relationship |
Function |
| Mitochondrial ribosome |
Component |
Site of mitochondrial translation |
| mtDNA-encoded proteins |
Product |
OXPHOS complex subunits |
| Mitochondrial tRNA(Arg) |
Substrate |
Substrate for aminoacylation |
| ATP |
Energy source |
Required for aminoacylation |
| Other mtARS enzymes |
Partner |
Coordinated mitochondrial translation |
- Mitochondrial enhancers: Improve mitochondrial function despite translation defects
- Antioxidants: Combat increased oxidative stress
- Energy supplements: Support cellular energy levels
- Viral vector delivery of wild-type MARS2
- CRISPR-based correction of pathogenic variants
- Physical therapy for spasticity
- Occupational therapy
- Assistive devices for mobility
Zebrafish studies show:
- Morpholino knockdown causes motor defects
- Mitochondrial dysfunction in neural tissues
- Axonal pathfinding abnormalities
- Mars2 knockout: Embryonic or early postnatal lethal
- Conditional knockouts: Tissue-specific deletion reveals neuronal functions
MARS2 mutations impair mitochondrial translation through several mechanisms:
- Reduced aminoacylation: Loss of MARS2 activity reduces charged tRNA(Arg) levels
- Ribosome stalling: Uncharged tRNA causes ribosome pausing
- Incomplete protein synthesis: Truncated OXPHOS proteins are produced
- Assembly defects: Incomplete proteins cannot form functional complexes
The resulting OXPHOS deficiency has multiple consequences:
- Complex I deficiency: Most commonly affected
- Complex III and IV: Secondary effects
- ATP depletion: Insufficient energy for cellular functions
- ROS overproduction: Electron leak from damaged complexes
Why are neurons particularly susceptible:
- High energy demand: Neurons require continuous ATP for ion pumping
- Limited glycolytic capacity: Cannot compensate for mitochondrial failure
- Axonal length: Long axons require extensive mitochondrial distribution
- Calcium handling: Mitochondria buffer calcium; dysfunction leads to excitotoxicity
flowchart TD
A["MARS2 Mutations"] --> B["Reduced tRNA Aminoacylation"]
B --> C["Impaired Mitochondrial Translation"]
C --> D["OXPHOS Deficiency"]
D --> E["Reduced ATP Production"]
D --> F["Increased ROS"]
E --> G["Neuronal Energy Crisis"]
F --> H["Oxidative Stress"]
G --> I["Synaptic Dysfunction"]
H --> I
G --> J["Axonal Degeneration"]
H --> J
I --> K["Neurodegeneration"]
J --> K
L["Corticospinal Tract"] --> M["Long Axons Affected"]
M --> J
style A fill:#ffcdd2,stroke:#333
style D fill:#f44336,stroke:#333,color:#fff
style K fill:#b71c1c,stroke:#333,color:#fff
style L fill:#fff9c4,stroke:#333
MARS2 mutations causing hereditary spastic paraplegia:
| Mutation Type |
Frequency |
Effect |
| Nonsense |
Common |
Truncated protein |
| Frameshift |
Common |
Premature stop |
| Splice-site |
Less common |
Exon skipping |
| Missense |
Rare |
Partial loss |
- Biallelic null mutations → severe SPG74
- Missense variants → variable presentation
- Compound heterozygosity → intermediate severity
Core Features:
- Progressive lower limb spasticity
- Gait disturbance
- Lower limb weakness
- Hyperreflexia
Additional Features (variable):
- Intellectual disability
- Peripheral neuropathy
- Optic atrophy
- Seizures (rare)
- Childhood to early adulthood
- Typically before age 20
- Progressive course over decades
- OXPHOS enzyme activities: Reduced complex I/IV in muscle
- Lactate: Elevated in plasma and CSF
- Pyruvate: Often elevated
- Fibroblast studies: Patient-derived cells show defects
- Targeted panels: Include MARS2 and other mtARS genes
- Whole exome sequencing: Identify pathogenic variants
- Sanger confirmation: Validate variants
- Other forms of HSP (SPG4, SPG5, etc.)
- Primary lateral sclerosis
- Hereditary ataxias
- Mitochondrial disorders
Symptomatic:
- Spasticity management (baclofen, tizanidine)
- Physical therapy
- Orthopedic interventions
- Assistive devices
Metabolic Support:
- CoQ10 supplementation
- Lipoic acid
- Vitamin supplementation
Mitochondrial Modulation:
- Small molecules enhancing mitochondrial function
- Antioxidants targeting mitochondrial ROS
- ATP supplementation strategies
Gene Therapy Approaches:
- Viral vector delivery of wild-type MARS2
- CRISPR-based gene editing
- mRNA delivery for protein expression
| Gene |
Protein |
Associated Diseases |
| MARS2 |
Mitochondrial Arg-tRNA synthetase 2 |
SPG74, ALS |
| RARS2 |
Mitochondrial Arg-tRNA synthetase |
Pontocerebellar hypoplasia |
| DARS2 |
Mitochondrial Asp-tRNA synthetase |
Leukoencephalopathy |
| EARS2 |
Mitochondrial Glu-tRNA synthetase |
LTBL |
| PARS2 |
Mitochondrial Pro-tRNA synthetase |
Epilepsy |
- Patient fibroblasts: Show OXPHOS defects
- iPSC-derived neurons: Model disease mechanisms
- CRISPR-edited cells: Isogenic controls
- Zebrafish: Morpholino knockdowns, motor phenotype
- Drosophila: Homolog studies
- Mouse: Conditional knockouts
- Sissler et al., Mitochondrial aminoacyl-tRNA synthetases in disease (2017)
- Beyer et al., Aminoacyl-tRNA synthetases in neurodegeneration (2019)
- Antonellis et al., Role of ARS in neurological disease (2019)
- Bayat et al., Mitochondrial dysfunction in HSP (2017)
- Eskier et al., MARS2 mutations cause SPG74 (2018)
- Martin et al., Mitochondrial translation and disease (2019)
- Ibrahim et al., Targeting mitochondrial translation (2020)
- Wallace, Mitochondrial genetics in neurodegeneration (2018)
- Suomalainen & Kaurola, Mitochondrial DNA mutations in disease (2011)
- Gorman et al., Mitochondrial diseases in adults (2016)
The corticospinal tract neurons affected in HSP have exceptionally long axons that connect the motor cortex to the spinal cord. These axons span up to a meter in humans and require massive amounts of ATP for:
- Axonal transport: Mitochondria must be transported along microtubules to meet energy demands at distant synapses
- Ion homeostasis: Voltage-gated channels require continuous ATP-powered pumping
- Synaptic function: neurotransmitter release and recycling is energy-intensive
- Cytoskeletal maintenance: Axonal integrity requires constant maintenance
When MARS2 mutations impair mitochondrial translation, ATP production falls below the threshold required to maintain these functions, leading to axonal degeneration beginning at the distal ends.
Impaired mitochondria generate increased reactive oxygen species:
- Electron leak: Damaged complexes I and IV leak electrons to oxygen
- Superoxide formation: Produces superoxide anion
- Hydrogen peroxide: Conversion by SOD produces H2O2
- Hydroxyl radical: Fenton chemistry produces highly damaging OH-
- DNA damage: Nuclear and mitochondrial DNA oxidized
- Protein oxidation: Enzymes inactivated, aggregates form
- Lipid peroxidation: Membrane damage, further impairing function
Cells attempt to compensate for mitochondrial dysfunction:
- Mitochondrial biogenesis: PGC-1α upregulates to create new mitochondria
- Unfolded protein response: Attempts to handle misfolded OXPHOS proteins
- Autophagy: Damaged mitochondria are removed via mitophagy
- Glycolytic shift: Attempt to generate ATP anaerobically
These mechanisms eventually fail as dysfunction progresses.
- Mild gait disturbance
- Subtle spasticity
- Normal activities possible
- Progressive spasticity
- Gait difficulties requiring aids
- Lower limb weakness
- Fatigability
- Severe spasticity
- Wheelchair dependence
- Contractures
- Potential complications (UTIs, pneumonia)
- Neurology: Diagnosis, monitoring, medication management
- Physical therapy: Maintain mobility, prevent contractures
- Occupational therapy: Adaptive equipment, daily activities
- Orthopedics: Surgical interventions if needed
- Genetics: Counseling for families
- Oral medications: Baclofen, tizanidine, benzodiazepines
- Botulinum toxin: Focal injections
- Intrathecal baclofen: For severe cases
- Surgical: Tenotomy for contractures
- Regular neurological assessment
- Gait analysis
- Pulmonary function (if severe)
- Developmental assessment (children)
- Metabolomic markers: α-Ketoglutarate, succinate ratios
- Proteomic markers: OXPHOS subunit levels
- Functional assays: Mitochondrial respiration in fibroblasts
- Enhance mitochondrial translation: Small molecules
- Reduce oxidative stress: Antioxidants
- Increase ATP production: Metabolic modulators
- Gene therapy: Restore MARS2 expression
- No MARS2-specific trials yet
- Trials of CoQ10 and mitochondrial supplements
- Trials of gene therapy for other mtARS disorders
Zebrafish provide valuable insights:
- Morpholino knockdown: Recapitulates human phenotype
- Motor defects: Swimming abnormalities
- Mitochondrial dysfunction: Complex I deficiency
- Axonal defects: Peripheral nerve abnormalities
- Rescue studies: Show proof-of-concept for therapy
- Mitochondrial supplements partially rescue phenotype
- Gene expression restoration possible
- Early intervention more effective
- Corticospinal tract: T2 hyperintensity in some cases
- Brainstem: Variable findings
- Cerebellum: May show atrophy
- Spinal cord: Thin cord in some cases
- DTI: Shows white matter tract damage
- MRS: Elevated lactate in some cases
- Functional MRI: Altered connectivity
- Normal life expectancy in isolated HSP
- Reduced in complex phenotypes
- Variable based on mutation severity
- Impact varies with disease severity
- Early intervention improves outcomes
- Supportive care essential
- Autosomal recessive inheritance
- 25% recurrence risk for carrier parents
- Testing available for at-risk family members
- Preimplantation genetic diagnosis possible
- Available for confirmed pathogenic variants
- Allows informed family planning
MARS2 mutations cause hereditary spastic paraplegia type 74 through impaired mitochondrial translation and resulting OXPHOS deficiency. The disease primarily affects long corticospinal tract axons, leading to progressive spasticity and gait disturbance. Understanding the molecular mechanisms has identified potential therapeutic targets, though effective treatments remain to be developed. Genetic counseling is essential for affected families.